About The Study:

RSV, or respiratory syncytial virus, is a common respiratory virus that usually causes mild, cold-like symptoms. Typically, healthy people can recover in 1 – 2 weeks, but RSV can be serious.  Infants and older adults are more likely to develop severe RSV and may need hospitalization, like COVID–19.  

Since both vaccines are currently recommended to similar patient populations, Rochester Clinical Research is currently conducting a clinical trial evaluating the effectiveness of a COVID-19 and RSV vaccine given on the same day, compared to administration of RSV and COVID-19 vaccines given one month apart.  All patients participating in the trial will receive a COVID and RSV vaccine (both FDA approved) vaccine. 

The study lasts 6 – 7 months, with 3 visits to our office, and one telephone call. Compensation for time and travel will be available.  

There is no cost to participate in this study and health insurance is not required nor needed. 

Qualifications

  • At least 50 years old
  • Have not received a COVID-19 vaccine for at least 3 months
  • Have not tested positive for COVID-19 in the last 3 months
  • Have never received an RSV vaccine
  • *Please note, other exclusions may apply.